Great research Canute40, think this shows that BBI is a great choice, especially with Novarum the smartphone DX reader tech. It shows the joined up thinking and great leadership coming from Sir Al. We'll have a Brilliant lightning fast test that combined with the reader should be able to plug straight into track and trace. This isn't just testing, it has the potential to be a complete system for saving a country.
Test
Report
Track
Trace
Isolate
Massive opportunity for BBI.
Net new customer with a totally bleeding edge technology and transformational offering.
The opportunity to produce millions of new tests.
The opportunity potential to work with Avacta on other new tests and products to bring to market.
Competitive advantage for BBI to scale up their manufacturing to service Avacta before other manufacturers get brought online.
The proposed easing of restrictions that were due to take place tomorrow is being delayed by 2 weeks. The UK Govt are definitely being more proactive about making quicker decisions and executing on them. https://www.bbc.co.uk/news/live/world-53605329
FDA opens door to rapid, at-home screening for COVID-19 https://www.usatoday.com/story/news/2020/07/29/fda-opens-door-rapid-home-covid-19-tests/5536528002/
I've emailed the writer to point out this new guidance was very likely the result of the FDA working closely with Avacta
Interesting video snippet, Trump talks about thousands and thousands of kits being made right now which give you a 15 minute or 5 minute test result https://twitter.com/Tweet_trader01/status/1285816646100307969?s=19
Really wish I had the funds to top up more, am still waiting for an old corporate pension to move funds into a new SIPP which should be any day now. I'll be gutted if the news arrives before the SIPP receives the transfer.
The new FDA template included this section so could be a pointer...
5) Test Result Reporting:
All test results will be reported to healthcare providers and relevant public health authorities in accordance with local, state, and federal requirements, using appropriate LOINC and SNOMED codes, as defined by the Laboratory In Vitro Diagnostics (LIVD) Test Code Mapping for SARS-CoV-2 Tests provided by CDC.
You should describe how you will ensure all users of the test can report all test results to public health and/or other authorities to whom reporting is required, in accordance with local, state, and federal requirements. The approach adopted should facilitate reporting by all users and be easy to use and understand. There are several options to allow for reporting of test results including, but not limited to: automatic reporting through mobile app, instructions directing users to a website where reporting is easily facilitated, etc. FDA is open to alternative approaches to reporting that ensure appropriate reporting.
You should also describe how test reporting will capture the appropriate LOINC and SNOMED codes, in addition to location data, and other patient information that may be relevant or required.
6) Mobile Applications and Software
Any smartphone application should be simple. Error messages should be readily understandable, and troubleshooting should be included in the device instruction. The display should promote understanding of results and what patients should do next, including how to care for themselves and when to seek follow up care.
Please list and describe any mobile applications, software or web applications used with the test.